Search Results

You are looking at 231 - 240 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?

Edmond Marzbani and Elihu Estey

, 6 patients were admitted for febrile neutropenia, and 3 cases of nonfatal Pneumocystis jiroveci were seen. 13 , 14 In a Japanese case series of 10 patients, a less-intensive regimen of ATRA, 6-MP, and MTX was used for maintenance, and no patients

Full access

Prostate Cancer, Version 1.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho

Radium-223 was well tolerated. Grade 3/4 hematologic toxicity was low (3% neutropenia, 6% thrombocytopenia, and 13% anemia), possibly because of the short range of radioactivity. 23 Fecal elimination of the agent led to generally mild nonhematologic side

Full access

Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma

Senthil Damodaran, Ewa Mrozek, David Liebner, and Kari Kendra

duration of 1 year. Therapy was well tolerated except for the development of flu-like symptoms, nausea, and fatigue. However, she required a 30% dose reduction of interferon in December 2011 for increased pain and neutropenia. She completed her last

Full access

A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

. The patient was then treated with erlotinib for 2 cycles but developed rapid disease progression. The patient was then placed briefly on docetaxel, but mucositis and neutropenia were dose-limiting. Anaplastic lymphoma kinase (ALK) fluorescence in situ

Full access

Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice

Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth

Javaheri KR Yin Y Gill S . Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer . J Gastrointest Cancer 2014 ; 45 : 460 – 465 . 19. Sanoff HK Carpenter WR Freburger

Full access

Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

and its side effects, such as neutropenia; and infection leading to antibiotic exposure. 4 , 8 Additionally, graft-versus-host disease (GVHD) has been associated with CDI. 10 – 12 A study using the National Inpatient Sample from 2005 to 2011 reported

Full access

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera

overall and grade 3/4 toxicities in comparison with doublets ( Table 3 ), particularly with more grade 3/4 anemia, stomatitis, febrile neutropenia (10.4% vs 6.5%), hepatic toxicity (15.8% vs 9.2%), and toxicity-related hospitalization (30.7% vs 22

Full access

Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib

James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos

/kg/d via a 7-day continuous infusion and experienced a hematologic CR. This remission was more durable, but the patient experienced a relapse again almost 5 years later, with neutropenia and thrombocytopenia. He then received 12 doses of pentostatin, 4 mg

Full access

Development of a Hematology/Oncology ICD-10 Documentation Job Aid

Daniel B. Martin, Sean Silas, Audrey Covner, Paul C. Hendrie, and F. Marc Stewart

the documentation of disease side effects and complications surrounding treatment (eg, chemotherapy-induced neutropenia, fatigue, anemia of chronic disease), and of nonspecialty codes (eg, diabetes, hypertension). These comorbidities will be assessed

Full access

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the